
Robotrak
Offers ophthalmic photocoagulator, an automatic diagnosis and treatment system.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
* | N/A | Series B | |
Total Funding | 000k |
Related Content
Robotrak Technologies Co., Ltd. is a health technology firm specializing in advanced ophthalmic medical devices. Founded in 2017 and headquartered in Nanjing, China, the company develops and provides solutions for vision care across all age groups, from adolescents to the elderly. Its operations are global, with research and development centers in Nanjing that support an integrated network of research, production, and marketing. Robotrak is a privately held, venture capital-backed company that has completed four funding rounds with investors including Nanjing New Industry Investment Group and Co-Stone Capital.
The company's business is centered on creating and manufacturing high-tech ophthalmic equipment that addresses a range of eye health issues, including the diagnosis and treatment of fundus diseases, myopia control in adolescents, and the development of functional contact lenses. Revenue is generated through the sale of these specialized medical devices to healthcare providers and research institutions. For instance, its MONA Adaptive Optics Scanning Laser Ophthalmoscope was installed at the University of Houston College of Optometry, signifying its expansion into the North American research and clinical market. Robotrak serves a diverse client base that includes hospitals, research universities, and clinics.
Robotrak's product portfolio is built upon a foundation of core technologies such as adaptive optics, eye tracking, artificial intelligence, and precise laser navigation. A key product is the MONA Adaptive Optics Scanning Laser Ophthalmoscope (AO-SLO), which was the first of its kind to be commercialized globally and allows for the observation of retinal structures at a microscopic level. Another significant product is the SARIS retinal imaging system, a multi-modal device for in-vivo fundus detection in small animals that combines scanning laser ophthalmoscope (SLO) and optical coherence tomography (OCT) techniques. The company holds over 169 intellectual property patents for its technologies. These products provide detailed imaging and quantitative analysis of photoreceptors and blood flow, assisting clinicians and researchers in diagnosing and managing eye conditions more effectively.
Keywords: ophthalmic devices, medical technology, vision care, fundus disease, myopia control, adaptive optics, retinal imaging, eye tracking, artificial intelligence, laser navigation, scanning laser ophthalmoscope, optical coherence tomography, diagnostic equipment, HealthTech, medical imaging, vision science, ophthalmology research, eye health, Nanjing, China